Intuitive Surgical drops 10% despite beating Q2 estimates on procedure growth outlook

What happened

Intuitive Surgical delivered $2.80 adjusted earnings per share for Q2 2026, exceeding analyst estimates by $0.29, while revenue climbed 19% year-over-year to $2.89 billion. The company placed 468 da Vinci surgical systems during the quarter, up from 395 a year earlier, and overall procedure volumes grew 16%. Despite the strong quarterly performance, management projected full-year 2026 da Vinci procedure growth of 13.5% to 15.5%, with results expected near the 14.5% midpoint. The company also forecast an adjusted gross margin of 68% to 69%, including a one percentage point hit from tariffs.

Why the stock moved

Shares fell 10.9% following the earnings release, as the full-year procedure growth guidance disappointed investors who had expected stronger acceleration. While Intuitive beat quarterly estimates and demonstrated continued adoption of its robotic surgery platforms, the guidance suggested slower momentum than Wall Street anticipated. The stock decline reflects concern that demand for elective procedures using da Vinci systems may not meet elevated investor expectations, even as the company's installed base reached a record 11,710 systems worldwide.

Bigger picture

Intuitive Surgical dominates the robotic surgery market, with its da Vinci platform used in hospitals globally for minimally invasive procedures. The company's Ion platform saw procedures jump 36%, demonstrating expansion beyond traditional surgery into areas like lung biopsy. However, procedure growth can be sensitive to hospital budgets, patient volumes, and broader healthcare policy shifts. The guidance also highlighted ongoing tariff pressures affecting medical device manufacturers, which could squeeze margins even as adoption continues. With an installed base growing 12% year-over-year, Intuitive benefits from recurring revenue as hospitals use more instruments per procedure.

What investors watch

Investors will monitor whether actual procedure volumes trend toward the higher or lower end of the guidance range throughout 2026, as this drives recurring revenue from instruments and accessories. Watch for updates on da Vinci 5 adoption, which accounted for 246 of 468 system placements this quarter, as the latest platform could drive higher utilization. Tariff developments and their impact on gross margins remain a wildcard. Additionally, any healthcare policy changes affecting hospital capital spending or reimbursement rates for robotic procedures could shift demand trends.